Article Information
History
- August 29, 2024.
Article Versions
- Version 1 (March 19, 2024 - 21:24).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Steven A Anderson, PhD, MPP1,
- Elizabeth R Smith, BS2,
- Zhiruo Wan, MS2,
- Kandace L Amend, PhD, MPH3,
- Alex Secora, PhD4,
- Djeneba Audrey Djibo, PhD, MSBME5,
- Kamran Kazemi, BS2,
- Jennifer Song, MA, MURP3,
- Lauren E Parlett, PhD6,
- John D Seeger, DrPH, PharmD3,
- Nandini Selvam, PhD, MPH4,
- Cheryl N McMahill-Walraven, PhD, MSW5,
- Mao Hu, BS2,
- Yoganand Chillarige, MPA2 and
- Richard A Forshee, PhD1,*
- 1US Food and Drug Administration, Silver Spring, MD, USA
- 2Acumen LLC, Burlingame, CA, USA
- 3Optum Epidemiology, Boston, MA, USA
- 4IQVIA, Falls Church, VA, USA
- 5CVS Health, Blue Bell, PA, USA
- 6Carelon Research, Inc., Wilmington, DE, USA
- ↵*Address correspondence to
: Richard A. Forshee, PhD, Deputy Director, Office of Biostatistics and Pharmacovigilance, Center for Biologics Evaluation and Research, U.S. Food & Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD, 20993, richard.forshee{at}fda.hhs.gov, (240) 402-8631
Posted August 29, 2024.
Febrile Seizure Risk Following Monovalent COVID-19 mRNA Vaccination in US Children Aged 2-5 Years
